Jupiter Neurosciences, Inc. (JUNS)
| Market Cap | 8.67M -56.4% |
| Revenue (ttm) | 40,448 |
| Net Income | -9.18M |
| EPS | -0.26 |
| Shares Out | 36.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,941,758 |
| Open | 0.2549 |
| Previous Close | 0.2708 |
| Day's Range | 0.2300 - 0.2572 |
| 52-Week Range | 0.1721 - 3.3300 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 30.00 (+12,457.56%) |
| Earnings Date | May 14, 2026 |
About JUNS
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson’s disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alz... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for JUNS stock is "Strong Buy" and the 12-month stock price target is $30.0.
News
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
Cash Runway Extended to Finance the Parkinson's Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("J...
Jupiter Neurosciences announces pricing of $2M registered direct offering
Jupiter Neurosciences (JUNS) announced it has entered into a securities purchase agreement for the purchase and sale of 7.14M shares of common stock in a registered direct offering. The gross…
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system diso...
Jupiter Neurosciences to acquire licensing rights to ALA-002 for $3.33M upfront
Jupiter Neurosciences (JUNS) announced that it has entered into term sheet to acquire exclusive United States licensing rights to ALA-002, the drug candidate of PharmAla Biotech. Pursuant to the term…
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit
Jupiter, Florida--(Newsfile Corp. - May 4, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, announ...
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14
Jupiter, Florida--(Newsfile Corp. - April 13, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, wil...
Jupiter Neurosciences to present progress at Mar-a-Lago investor dinner
Jupiter Neurosciences (JUNS) announces that members of senior management have been invited, as the only company this evening, to present its progress at a private investor dinner taking place Wednesda...
Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago
JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central...
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS...
Jupiter Neurosciences expands Nugevia addressable market
Jupiter Neurosciences (JUNS) announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia consumer longevity product line. This initiative reinfo...
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
Nugevia ™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neur...
Join Jupiter Neurosciences' Exclusive Live Investor Webinar and Q&A Session on January 6
Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resv...
Jupiter Neurosciences to Participate in NobleCon21
Jupiter, Florida--(Newsfile Corp. - December 2, 2025) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic...
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
Financing designed to support Phase 2 Parkinson's trial and accelerate Nugevia ™ product line growth
Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador
Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation
Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science
Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Compan...
Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq compliance follows positive upward trend in Company's Stock Price Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a...
Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfolio
Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador
Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resv...
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial
Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resv...
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline ...
Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline ...